CTLA4 and cancer: Given this prominent role of the PD-1/PD-L1 and CTLA4 pathways in cancer immune evasion, anti-PD-1/PD-L1 and anti-CTLA4 drugs, and their combinations, have become the current paradigm of IBC-based cancer immunotherapy.